stress urinary incontinence following failed sling. The outcomes assessed were patient reported improvement, need for further interventions for incontinence and the Michigan Incontinence Symptom Index (M-ISI), which is a validated questionnaire that has a range of 0-32 for symptom score and 0-8 for bother score with higher scores indicating worse incontinence. Values for questionnaires were obtained from the patient's pre-procedure visit and following their last injection. Demographic data, type of prior sling procedure, and type of bulking agent utilized were also reported.
stress urinary incontinence following failed sling. The outcomes assessed were patient reported improvement, need for further interventions for incontinence and the Michigan Incontinence Symptom Index (M-ISI), which is a validated questionnaire that has a range of 0-32 for symptom score and 0-8 for bother score with higher scores indicating worse incontinence. Values for questionnaires were obtained from the patient's pre-procedure visit and following their last injection. Demographic data, type of prior sling procedure, and type of bulking agent utilized were also reported.
RESULTS METHODS: Following IRB approval, a prospective database of non-neurogenic women who underwent MPQ injection for SUI due to intrinsic sphincter deficiency under light anesthesia, and were followed for > 6 months was reviewed. Postoperative retention was defined as inability to void after injection requiring a catheter for 24-48 hours, or difficulty voiding immediately postoperatively (post void residual > 200 ml by bladder scan) as charted in the recovery room electronic medical record. Women on self-catheterization, with a supra-pubic tube, those who had a concomitant procedure, or with follow up < 6 months were excluded. Success was defined as patient reporting sufficient continence for not desiring any additional therapy, ie dry or with rare leakage at last visit. Patients were divided into Group 1: Retention post-operatively and Group 2: no retention postoperatively.
RESULTS: From August 2011 to December 2013, 68 of 92 women met all inclusion criteria. Overall 24/68 (35%) patients had retention after surgery. Similar baseline demographics for Group 1 (N¼24) and Group 2 (N¼44) are shown in Table 1 . Success was 88% for group 1 (21/24) versus 23/44 (52%) in group 2 (p<0.008) at median follow-up of 25 (7-52) months in group 1 and 24 (7-53) months in group 2. Similarly there was significantly higher number of patients who were completely dry in Group 1 (19/24) than in Group 2 (8/24) (p< 0.0001). Patients in Group 2 needed significant higher number of repeat endoscopic injections compared to Group 1 (p<0.002) CONCLUSIONS: Postoperative transient retention was seen in nearly one third of women immediately after MPQ injection. At a median follow-up of 2 years, these women remained dry or were markedly improved, and did not desire additional SUI therapy more so than those who voided well initially.
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INTRODUCTION AND OBJECTIVES:
The morbidity related to artificial urinary sphincter (AUS) implantation in women is usually considered as the drawback which has limited its widespread. In order to decrease this morbidity, several teams have recently reported the use of a robotic approach to implant the AUS in female patients. The aim of this study was to report the perioperative and functional outcomes of robotic AUS implantation in women.
METHODS: All female patients who underwent robotic AUS implantation between 2013 and 2016 in five institutions were included in a retrospective study. The indication for AUS implantation was type III stressurinary incontinence and intrinsic sphincter deficiency defined as a combination of a low urethral closure pressure (< 30 cm H2O), loss of urethral mobility and a negative Marshall/Bonney test (urine leakage on straining or coughing not corrected by urethral support). The robotassisted approach was the only approach used for AUS implantation in women during the study period in the five institutions involved. The primary enpoint was the functional outcome categorized as : cured (complete continence, i.e. no pads used), improved (decrease > 80% in number of pads per day or in urine leakage assessed through pad test) or failure decrease < 80% in number of pads per day or urine leakage assessed through pad test).
RESULTS: Forty patients underwent robotic AUS implantation by ten surgeons during the study period (1 to 12 procedures/surgeon). There were 6 intraoperative complications: 4 bladder neck injuries and 2 vaginal injuries. Nine patients experienced postoperative complications (22.5%) but only two were Clavien ¼3 (5%) : one AUS explantation due to vaginal erosion and one reoperation for device infection. After a median follow-up of 12 months, explantation of the AUS device was needed in one case (2.5%) due to vaginal erosion. Thirty-five patients were cured of their incontinence (87.5%), three were improved (7.5%) and the procedure failed in two patients (5%).
CONCLUSIONS: This study is the first multicenter series asessing the outcomes of robotic AUS implantation in women. Despite a limited number of cases performed per surgeon, perioperative and functional outcomes appeared at least similar to those reported in large series of open AUS implantation from tertiary referral centers. Further data are needed tho confirm the findings of the present report.
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